Details of the Drug

General Information of Drug (ID: DMRM0JV)

Drug Name

Nalidixic acid

Synonyms

Betaxina; Cybis; Dixiben; Dixinal; Eucistin; Innoxalon; Jicsron; Kusnarin; Nalidicron; Nalidixan; Nalidixane; Nalidixate; Nalidixic; Nalidixin; Nalitucsan; Nalix; Nalurin; Narigix; Naxuril; NegGram; Negram; Nevigramon; Nicelate; Nogram; Poleon; Sicmylon; Specifen; Specifin; Unaserus; Uralgin; Uriben; Uriclar; Urisal; Urodixin; Uroman; Uroneg; Uronidix; Uropan; Wintomylon; Wintron; Acide nalidixico; Acide nalidixico [Italian]; Acide nalidixique; Acide nalidixique [French]; Acido nalidissico; Acido nalidissico [DCIT]; Acido nalidixico; Acidum nalidixicum; NALIDIXATE SODIUM; Naladixic acid; Naldixic acid; Nalidic acid; Nalidixinic acid; Nalidixic acid USP27; WIN 183203; Acid, Nalidixic; Acide nalidixique [INN-French]; Acido nalidixico [INN-Spanish]; Acidum nalidixicum [INN-Latin]; N-1200; NegGram (TN); Neggram (TN); Sodium Nalidixic Acid, Anhydrous; Sodium Nalidixic Acid, Monohydrate; Sodium,Nalidixate; WIN 18,320; WIN-18320; Wil 18,320; Wintomylon (TN); ZERO/002632; WIN-18320 (TN); Nalidixic acid (JP15/USP/INN); Nalidixic acid [USAN:INN:BAN:JAN]; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico [Italian]; 1,4-Dihydro-1-ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid; 1,4-Dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure [German]; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxilic acid; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 1-ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-ca rboxylic acid; 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthidin-4-one; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one

Indication

Disease Entry	ICD 11	Status	REF
Urinary tract infection	GC08	Approved	[1], [2]

Therapeutic Class

Antibiotics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

232.23

Topological Polar Surface Area (xlogp)

1.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability: 96% of drug becomes completely available to its intended biological destination(s) [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.1 - 2.5 hours [5]
Metabolism: The drug is metabolized via the hepatic [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 287.2016 micromolar/kg/day [7]
Water Solubility: The ability of drug to dissolve in water is measured as 0.054 mg/mL [3]

Chemical Identifiers

Formula: C12H12N2O3
IUPAC Name: 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid
Canonical SMILES: CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O
InChI: InChI=1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17)
InChIKey: MHWLWQUZZRMNGJ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4421
ChEBI ID: CHEBI:100147
CAS Number: 389-08-2
DrugBank ID: DB00779
TTD ID: D07JGT
INTEDE ID: DR2296

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN; TOP2B_HUMAN	Inhibitor	[8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Nalidixic acid

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Nalidixic acid and Plazomicin.	Urinary tract infection [GC08]	[15]
-----------

Coadministration of a Drug Treating the Disease Different from Nalidixic acid (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Idarubicin	DMM0XGL	Minor	Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Idarubicin.	Acute myeloid leukaemia [2A60]	[16]
Aminophylline	DML2NIB	Moderate	Decreased metabolism of Nalidixic acid caused by Aminophylline mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[17]
Temozolomide	DMKECZD	Minor	Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Temozolomide.	Brain cancer [2A00]	[16]
Ketoprofen	DMRKXPT	Moderate	Additive CNS depression effects by the combination of Nalidixic acid and Ketoprofen.	Chronic pain [MG30]	[18]
Capecitabine	DMTS85L	Minor	Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Capecitabine.	Colorectal cancer [2B91]	[16]
Mestranol	DMG3F94	Moderate	Decreased absorption of Nalidixic acid due to formation of complexes caused by Mestranol.	Contraceptive management [QA21]	[19]
Mycophenolic acid	DMU65NK	Moderate	Altered absorption of Nalidixic acid due to GI flora changes caused by Mycophenolic acid.	Crohn disease [DD70]	[20]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Nalidixic acid caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[21]
Mefenamic acid	DMK7HFI	Moderate	Additive CNS stimulant effects by the combination of Nalidixic acid and Mefenamic acid.	Female pelvic pain [GA34]	[18]
Procarbazine	DMIK367	Minor	Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Procarbazine.	Hodgkin lymphoma [2B30]	[16]
Didanosine	DMI2QPE	Moderate	Decreased absorption of Nalidixic acid due to formation of complexes caused by Didanosine.	Human immunodeficiency virus disease [1C60-1C62]	[22]
Bempedoic acid	DM1CI9R	Major	Increased risk of tendinitis/tendon rupture by the combination of Nalidixic acid and Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[23]
Quinapril	DMR8H31	Moderate	Decreased absorption of Nalidixic acid due to formation of complexes caused by Quinapril.	Hypertension [BA00-BA04]	[21]
Givosiran	DM5PFIJ	Moderate	Increased risk of nephrotoxicity by the combination of Nalidixic acid and Givosiran.	Inborn porphyrin/heme metabolism error [5C58]	[15]
Probenecid	DMMFWOJ	Moderate	Decreased elimination of Nalidixic acid caused by Probenecid mediated competitive inhibition of renal tubular secretion.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[24]
Meclofenamic acid	DM05FXR	Moderate	Additive CNS stimulant effects by the combination of Nalidixic acid and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[25]
Ramelteon	DM7IW9J	Moderate	Decreased metabolism of Nalidixic acid caused by Ramelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[26]
Melatonin	DMKWFBT	Minor	Decreased metabolism of Nalidixic acid caused by Melatonin mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[15]
Tasimelteon	DMLOQ1V	Moderate	Decreased metabolism of Nalidixic acid caused by Tasimelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[27]
Iron	DMAP8MV	Moderate	Decreased absorption of Nalidixic acid due to formation of complexes caused by Iron.	Iron deficiency anaemia [3A00]	[28]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Nalidixic acid and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[29]
Alosetron	DML2A03	Moderate	Decreased metabolism of Nalidixic acid caused by Alosetron mediated inhibition of CYP450 enzyme.	Irritable bowel syndrome [DD91]	[30]
Lurbinectedin	DMEFRTZ	Minor	Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Lurbinectedin.	Lung cancer [2C25]	[16]
Fludarabine	DMVRLT7	Minor	Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Fludarabine.	Malignant haematopoietic neoplasm [2B33]	[16]
Mercaptopurine	DMTM2IK	Minor	Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Mercaptopurine.	Mature B-cell lymphoma [2A85]	[16]
Cytarabine	DMZD5QR	Minor	Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Cytarabine.	Mature B-cell lymphoma [2A85]	[16]
Ethinyl estradiol	DMODJ40	Moderate	Decreased absorption of Nalidixic acid due to formation of complexes caused by Ethinyl estradiol.	Menopausal disorder [GA30]	[19]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Nalidixic acid due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[31]
Deflazacort	DMV0RNS	Major	Increased risk of tendinitis/tendon rupture by the combination of Nalidixic acid and Deflazacort.	Muscular dystrophy [8C70]	[32]
Hydroxyurea	DMOQVU9	Minor	Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Hydroxyurea.	Myeloproliferative neoplasm [2A20]	[16]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Nalidixic acid and Bupropion.	Nicotine use disorder [6C4A]	[33]
Naproxen	DMZ5RGV	Moderate	Additive CNS stimulant effects by the combination of Nalidixic acid and Naproxen.	Osteoarthritis [FA00-FA05]	[18]
Carboplatin	DMG281S	Minor	Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Carboplatin.	Ovarian cancer [2C73]	[16]
Topotecan	DMP6G8T	Minor	Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Topotecan.	Ovarian cancer [2C73]	[16]
Aspirin	DM672AH	Moderate	Additive CNS stimulant effects by the combination of Nalidixic acid and Aspirin.	Pain [MG30-MG3Z]	[34]
Diflunisal	DM7EN8I	Moderate	Additive CNS depression effects by the combination of Nalidixic acid and Diflunisal.	Pain [MG30-MG3Z]	[18]
Ibuprofen	DM8VCBE	Moderate	Additive CNS depression effects by the combination of Nalidixic acid and Ibuprofen.	Pain [MG30-MG3Z]	[18]
Rasagiline	DM3WKQ4	Major	Decreased metabolism of Nalidixic acid caused by Rasagiline mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[15]
Choline salicylate	DM8P137	Moderate	Additive CNS stimulant effects by the combination of Nalidixic acid and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[25]
Salsalate	DM13P4C	Moderate	Additive CNS stimulant effects by the combination of Nalidixic acid and Salsalate.	Rheumatoid arthritis [FA20]	[18]
Meloxicam	DM2AR7L	Moderate	Additive CNS stimulant effects by the combination of Nalidixic acid and Meloxicam.	Rheumatoid arthritis [FA20]	[18]
Oxaprozin	DM9UB0P	Moderate	Additive CNS stimulant effects by the combination of Nalidixic acid and Oxaprozin.	Rheumatoid arthritis [FA20]	[18]
Dexamethasone	DMMWZET	Major	Increased risk of tendinitis/tendon rupture by the combination of Nalidixic acid and Dexamethasone.	Rheumatoid arthritis [FA20]	[32]
Asenapine	DMSQZE2	Moderate	Decreased metabolism of Nalidixic acid caused by Asenapine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[35]
Dactinomycin	DM2YGNW	Minor	Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Dactinomycin.	Solid tumour/cancer [2A00-2F9Z]	[16]
Methylprednisolone	DM4BDON	Major	Increased risk of tendinitis/tendon rupture by the combination of Nalidixic acid and Methylprednisolone.	Solid tumour/cancer [2A00-2F9Z]	[32]
Docetaxel	DMDI269	Minor	Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Docetaxel.	Solid tumour/cancer [2A00-2F9Z]	[16]
Mitoxantrone	DMM39BF	Minor	Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Mitoxantrone.	Solid tumour/cancer [2A00-2F9Z]	[16]
Prednisolone	DMQ8FR2	Major	Increased risk of tendinitis/tendon rupture by the combination of Nalidixic acid and Prednisolone.	Solid tumour/cancer [2A00-2F9Z]	[32]
Taxol	DMUOT9V	Minor	Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Taxol.	Solid tumour/cancer [2A00-2F9Z]	[16]
Doxorubicin	DMVP5YE	Minor	Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[16]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of nephrotoxicity by the combination of Nalidixic acid and Tacrolimus.	Transplant rejection [NE84]	[15]
-----------


⏷ Show the Full List of 52 DDI Information of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 071919.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	BDDCS applied to over 900 drugs
4	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1988 Aug;32(8):1182-6.
9	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10	Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
11	Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
12	Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
13	Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.
14	Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.
15	Cerner Multum, Inc. "Australian Product Information.".
16	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
17	Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986): 187-93. [PMID: 3542945]
18	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
19	Friedman CI, Huneke AL, Kim MH, Powell J "The effect of ampicillin on oral contraceptive effectiveness." Obstet Gynecol 55 (1980): 33-7. [PMID: 7188714]
20	Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
21	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
22	Deppermann KM, Lode H "Fluoroquinolones: interaction profile during enteral absorption." Drugs 45 Suppl 3 (1993): 65-72. [PMID: 7689454]
23	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
24	Dash H, Mills J "Letter: Severe metabolic acidosis associated with nalidixic acid overdose." Ann Intern Med 84 (1976): 570-1. [PMID: 1275361]
25	Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
26	Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
27	Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
28	Product Information. NegGram (nalidixic acid). Sanofi Winthrop Pharmaceuticals, New York, NY.
29	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
30	Product Information. Lotronex (alosetron). Glaxo Wellcome, Research Triangle Park, NC.
31	Canadian Pharmacists Association.
32	FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
33	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
34	Product Information. Avelox (moxifloxacin) Bayer, West Haven, CT.
35	Product Information. Saphris (asenapine). Schering-Plough Corporation, Kenilworth, NJ.